Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features / 实用肿瘤学杂志

ABSTRACT

Objective The objective of this study was to investigate the relationship between the molybdenum target imaging features and clinical signs of mammography,and the expression of HER-2 receptor in breast cancer patients with positive receptors of estrogen and progesterone. Methods One hundred and eleven patients with estrogen and progesterone receptor-positive breast canc-er who were admitted to our hospital from July to September 2017 were examined with mammography before operation. Immunohisto-chemical analysis was performed on breast cancer tissues. Pathological features and features related to mammography were analyzed af-ter operation. The relationship between clinicopathological features and mammography-related signs,and HER-2 expression was al-so analyzed statistically. Results Of the 111 patients,34 were HER-2 positive patients. There were significant difference between the observed indicators and the over-expression of HER-2(P<0. 05). These indicators included lymph node metastasis,calcifica-tion of the mass,margin of the mass,the shape of calcification,and the blood status of vessels. The mammography of patients with tri-ple positive breast cancer is more likely to manifest as lymph node enlargement,mass with calcification or simple calcification,margin-al burrs,granular calcification,and vascular thickening. Conclusion The expression of HER-2 in breast cancer patients with posi-tive estrogen and progesterone receptors can be reflected to some extent by lymph node metastasis,tumor with calcification,tumor mar-gin,calcification,calcification morphology and peripheral blood vessel thickening. In terms of clinical conditions,The biological behav-ior and characteristics of tumor can be inferred based on the clinicopathological features of the patient and the imaging findings of the mammography,providing a direction for the treatment and evaluation of prognosis in breast cancer patients.